Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6773199

CCOC(=O)CC(NC(=O)CNC(=O)c1cccc(N)c1)c1cccnc1.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.42
GPR139 Q6DWJ6 8/20 0.42
SUCNR1 Q9BXA5 2/20 0.41
ITGB3 P05106 3/20 0.40
ITGA2B P08514 2/20 0.40
ITGB1 P05556 1/20 0.40
ITGAV P06756 1/20 0.40
ITGA5 P08648 1/20 0.40
ITGB5 P18084 1/20 0.40
ITGB6 P18564 1/20 0.40
ITGB8 P26012 1/20 0.40
ITGA8 P53708 1/20 0.40
SLC6A9 P48067 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CTSL P07711 1/20 0.37
CTSS P25774 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6779290 0.94 ROCK2 (0.46) ROCK2GPR139SUCNR1ITGB3ITGA2B
SCHEMBL3835347 0.85 GPR139 (0.52) GPR139ITGB3ITGB1ITGAVITGA5
SCHEMBL7339949 0.83 ROCK2 (0.44) ROCK2GPR139SUCNR1ITGB3ITGA2B
SCHEMBL6772228 0.82 GPR139 (0.43) ROCK2GPR139SUCNR1ITGB3ITGA2B
SCHEMBL6773670 0.81 ROCK2 (0.43) ROCK2GPR139SUCNR1ITGB3ITGA2B
SCHEMBL7835665 0.81 ITGB3 (0.45) ROCK2GPR139SUCNR1ITGB3ITGA2B
SCHEMBL6773443 0.81 KMT2A (0.54) ROCK2MEN1KMT2AATMSMN1; SMN2
SCHEMBL7832728 0.81 ROCK2 (0.42) ROCK2GPR139SUCNR1ITGB3ITGA2B
SCHEMBL7338807 0.80 ROCK2 (0.45) ROCK2GPR139SUCNR1ITGB3ITGA2B
SCHEMBL7347786 0.79 GPR139 (0.49) ROCK2GPR139MEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed